Study objectives: This report reviews results of surgical management of lung cancer at a military medical center using the revised 1997 stage classification and determines the impact of the revised system on survival rates. It also compares our results with the recent reports from Japan and from a large, multinational study involving several institutions. 
I
n 1946, Denoix 1 introduced a system for the staging of lung cancer that was based on the estimation of the primary tumor (T), extent of involvement of locoregional lymph nodes (N), and presence or absence of distant metastasis (M). Unfortunately, no other system was found adequate until 4 decades later, when an international stage
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classification was developed by the American Joint Committee on Cancer (AJCC) in cooperation with the TNM Committee of the International Union Against Cancer (UICC), later reported by Mountain in 1986 . 2 This system remained the gold standard for lung cancer staging and was used worldwide for more than a decade. Several authors 3, 4 have since called attention to the wide variations in survival rates within the groups and noted the diversity and heterogeneity in the spectrum of disease stage. In 1996, the AJCC and UICC adopted several revisions to the 1986 stage classification, which were later reported by Mountain in 1997 (Table 1) . 5 Mountain and Dresler 6 have also resolved the inconsistencies in mediastinal lymph node stations classification as they relate to staging.
The purpose of this retrospective study is to review the survival characteristics of patients who underwent curative resection for lung cancer in a unique population of active duty military members, their dependents, and retired military members. The study also assesses the validity of the 1997 staging system. Our data included patients who underwent surgical resection with intent to cure using a staging system based on the pathologic examination of surgical specimens and lymph nodes and on the determination of the presence or absence of distant metastasis. Inoue and associates 7 recently reported a series of 1,310 patients from three Japanese institutions using the new stage classification. To our knowledge, ours is the first report from the United States that attempts to evaluate the validity of the revised stage classification on the basis of the results of surgical outcome in patients from a large, single military institution.
Materials and Methods
Between January 1984 and December 1996, 1,398 patients were registered in the Lung Cancer Tumor Registry at Walter Reed Army Medical Center (WRAMC). The medical records of the 552 patients who underwent surgical resection with intent to cure were analyzed. All patients were operated on by residents under the supervision of staff thoracic surgeons. Thoracic lymphadenectomy was not routinely performed during this period of review, but mediastinal nodal sampling was obtained from at least four mediastinal nodal stations for pathologic staging. Data extracted from each patient's medical record included age, gender, race, smoking history, risk factors, comorbid diseases, tumor histology and location, adjuvant and induction therapies, date of last follow-up, operative complications, deaths from any cause, and the status of disease at the time of death. The follow-up period ranged from 1 to 12 years (median, 3.5 years; mean, 4.0 years).
Other relevant information was obtained during clinic visits and from hospital charts and telephone contact with patients or their relatives. Survival probabilities were calculated by the Kaplan-Meier actuarial method 8 using a software package (Statistical Program for Social Sciences, 1994; SPSS Inc; Chicago, IL). The log rank test was used to compare survival probabilities between the stage subsets of the revised staging system. The survival rates for each stage were compared with recent reports based on the revised systems that were published by Mountain in 1997 5 and Inoue and associates in 1998. 7 A p value Ͻ 0.05 was considered statistically significant.
Results

Description of Population
Of the 1,398 patients with primary lung cancer, 552 patients (39.5%) underwent surgical resection with intent to cure. There were 392 men (71%) and 160 women (29%), with ages ranging from 31 to 95 years old (median, 64 years old; mean (Ϯ SD), 63 Ϯ 10 years old). Four hundred seventy-seven patients (86.4%) were white, 68 patients (12.3%) were African-American, and 7 patients (1.3%) were Asian. This is consonant with the ethnic composition of the US Army. Four hundred ninety-eight patients (90.2%) gave a smoking history of 50 to 80 packyears, and 11 patients (2%) had a Ͼ 80 pack-year smoking history, whereas 415 patients (75.2%) were still smoking at the time of diagnosis. Two hundred forty-eight patients (44.9%) were hypertensive, 149 patients (26.9%) had COPD, and 133 patients (24.1%) had FEV 1 Ͻ 1.5 L. One hundred ten patients (19.8%) gave a history of coronary artery disease, and 84 patients (15.2%) had coronary artery bypass surgery within 3 months to 10 years before surgery for lung cancer.
Tumor Histologic Findings and Location
Of the 552 patients operated on for lung cancer, adenocarcinoma constituted 51.4%; squamous cell carcinoma, 37.3%; small cell lung cancer, 4.3%; bronchioloalveolar carcinoma, 3.4%; large cell carcinoma, 2.5%; and undifferentiated carcinoma, 0.9%. Thirty-six percent of the tumors were in the right upper lobe, 30% were in the left upper lobe, 14% were in the right lower lobe, 13% were in the left lower lobe, and 6% were in the middle lobe. Two thirds of the tumors were in the upper lobes.
Surgical Procedure and Adjuvant Therapies
Lobectomy was performed in 424 patients (76.8%), pneumonectomy in 71 patients (12.8%), Before 1990, a less standardized approach was used as adjuvant therapy for locally advanced (stages IIIA and IIIB) disease. Cisplatin, in combination with other agents given in two to three cycles, or radiotherapy to a total dose of 60 Gy was used according to institution protocol in use at the time of treatment. However, a more standardized approach has evolved since 1990. This standardized approach involved both chemotherapy and radiotherapy. The agents most commonly used were cisplatin and vinblastine followed by radiation therapy to a total dose of 60 Gy. More recently, concomitant radiotherapy with chemotherapy (carboplatin and paclitaxel) has been used. Ongoing studies are addressing the sequencing of these modalities to determine the optimal effectiveness.
Survival Results
Eleven of the 552 patients died during the perioperative period for an overall operative mortality of 2%. One of the 57 patients (1.7%) who had limited resection died, 5 of the 424 patients (1.2%) who had lobectomy died, and 5 of the 71 patients (7%) who had pneumonectomy died. Major complications included persistent air leak that lasted Ͼ 7 days in 44 patients (8%), cardiac arrhythmia in 42 patients (7.6%), and various space problems that required additional tube drainage in 17 patients (3%). Other minor complications included atelectasis that required bronchoscopy in 15 patients (2.7%), ARDS in 11 patients (2%), reoperation for bleeding in 3 patients (0.54%), postpneumonectomy empyema with bronchopleural fistula in 3 patients (0.54%), and congestive heart failure and acute myocardial infarction in 2 patients (0.36%). Table 2 is a summary of the actuarial 5-year and 10-year survival rates (with median and mean [Ϯ SD] survival in years) of all patients by gender, race, and histologic findings. The overall actuarial 5-year and 10-year survival rates were 58% and 45%, respectively, with median survival of 3.3 years and mean of 3.9 Ϯ 0.1 years (Fig 1) . Table 3 shows the actuarial 5-year survival rates on the basis of the revised stage classification. There is a significant difference between the actuarial 5-year survival for stage IA (77%; median, 8 years; mean, 8.75 Ϯ 0.3 years) and those of stage IB (62%; median, 7.6 years; mean, 7.8 Ϯ 0.4 years; p ϭ 0.006) (Fig 2) . The actuarial 5-year survival for stage IIA was 57% (median, 5.4 years; mean, 5.0 Ϯ 0.6 years), compared with Table 4 shows the comparison of the actuarial 5-year survival rates of pathologic stages I to IIIA between Mountain's multinational series, 5 the Japanese series, 7 and the WRAMC series. There are striking similarities in the survival rates of these three series. Figure 1 shows the survival curve for the 552 patients. Figure 2 shows the survival curves for stages IA and IB subsets, and Figure 3 Figure 4 shows the survival curves of all the stage groupings on the basis of the revised stage classification. Figure 5 shows the survival curves on the basis of the status of lymph nodes found at surgery and from surgical specimens. Patients with negative nodes (N0) had better 5-year survival (66%) than did patients with positive N1 nodes (46%; p ϭ 0.002) and patients with positive N2 nodes (25%; p Ͻ 0.001). Our findings are similar to those of Mountain and Dresler, 6 who reported 5-year survival rates of 62%, 42%, and 25% for N0, N1, and N2 diseases, respectively.
Discussion
The past few years have brought significant changes to the classification and staging of lung cancer. These changes became necessary as a result of the heterogeneity of end results existing from the TNM categories within stage groups and of the need for greater specificity in stage classification. In 1996, the AJCC and UICC adopted several revisions to the 1986 stage classification, changes that were later published by Mountain in 1997 (Table 1) . 5 Also, Mountain and Dresler 6 have addressed the inconsistency in the mediastinal lymph node classification for accurate TNM staging. As a result of these changes, one of our patients with two separate nodules of squamous cell carcinoma in an ipsilateral primary tumor lobe, which were previously classified in an earlier publication 9 as synchronous multiple primary lung cancers, was restaged as T4.
Inoue and associates, 7 in a report of 1,310 patients from three institutions in Japan, confirmed the validity of the revised stage classification by Mountain. 5 We have assessed the validity of these changes and compared our experience from a single, large military institution with Mountain's multicenter, multinational series and the Japanese multicenter series. The unique system established in the military for medical care allows for excellent follow-up and close monitoring of all patients in the study. Our survival data also reveal close correlation with reported series 5,10 -13 from several large, civilian-based populations. The management of lung cancer remains surgical for stages I and II subsets and palliative with chemoradiotherapy for advanced disease. However, certain subsets of patients with stages IIIA and IIIB whose tumors initially appear as unresectable may become resectable after induction chemoradiotherapy. [13] [14] [15] [16] Our data further support the revisions to the staging system of lung cancer. Mountain, 5 Inoue and associates, 7 and Drings and coworkers 10 have noted differences in the survival rates among the various stages that are similar to our findings. However, we could not show any survival advantage that was statistically significant between stages IB and IIA IA  511  67  480  80  196  77  IB  549  57  271  65  146  62  IIA  76  55  57  57  17  57  IIB  375  39  187  NA  92  48  IIB subset  T2N1M0  288  39  141  42  50  48  T3N0M0  87  38  46  34  42  47  IIIA  399  23  291  NA  83  29  IIIA subset  T3N1M0  55  25  39  38  17 Despite the recent changes and advances, many areas for improvement exist. Although the survival rate for patients with T3N0M0 tumors appears favorable, we note that this survival advantage with T3N0M0 tumors is seen only in patients with tumors involving the chest wall and not with tumors involving the diaphragm or pericardium. Inoue and associates 7 also noted similar findings. They reported 35% actuarial 5-year survival for patients with T3N0M0 and T3N1M0 tumors invading the parietal pleura, 26% for tumors invading the chest wall, and 0% 3-year survival for tumors invading the diaphragm. Weksler and associates 17 found that 8 of the 4,668 patients (0.17%) who underwent exploration for resection of lung cancer at the Memorial SloanKettering Cancer Center from 1974 to 1995 had tumors invading the diaphragm. Four patients had T3N0 tumors, and the remaining four patients had T3N2 tumors. The mean survival for patients with T3N0 was 52.8 weeks: one patient was alive after 69.4 months, and the other three patients died of unrelated causes. Our three patients with tumors invading the diaphragm survived for 14, 15, and 16 months, whereas the patient with pericardial involvement survived for only 12 months. In contrast, the 33 patients with tumors invading the chest wall had a median survival of 3.9 years and a mean survival of 4.0 Ϯ 0.4 years. Although this number is small for any meaningful deduction, it is possible that chest wall tumors should retain the T3 designation, whereas tumors invading the diaphragm and pericardium should be designated as T4. There is also a need to further investigate the survival characteristics of patients with T3N0M0 disease to determine whether there are indeed significant survival differences within this tumor subset.
The 20% actuarial 5-year survival rate in the six patients with stage IIIB disease was indeed unexpectedly high. All six patients had T4N0 and T4N1 disease: three patients had tumors invading the thoracic vertebra, two patients had tumors invading the pulmonary artery, and one patient had two separate tumor nodules in the ipsilateral primary tumor lobe. All of the patients were operated on with intent to cure. None of these six patients had involvement of contralateral mediastinal (N3) nodes.
Conclusion
This study supports the recent changes in the staging system of lung cancer as reported by Mountain in 1997 5 and confirmed by Inoue and associates in 1998. 7 Our survival rates are similar, particularly among patients with stages I to IIIA. It would appear that the survival rates for the various stages and substages are in flux, and there may be a need for future modifications as we gain more knowledge about the biological behavior of lung cancer. The recent proposal by Margolis 18 for a simple numeric designation of the present 18 TNM groupings numbered from 0 to 17 would make the staging system easier to remember and less cumbersome for clinicians involved in the management of lung cancer. Figure 5 . Actuarial survival curves based on the nodal status of surgical-pathologic specimens. There are significant differences between N0 and N1 (p ϭ 0.002) and between N1 and N2 (p ϭ 0.001). These findings correlate with the recent report by Mountain and Dresler. 6 
